Literature DB >> 26935513

Osteoporosis in Gastrointestinal Diseases.

Iwona Krela-Kaźmierczak1, Aleksandra Szymczak1, Liliana Łykowska-Szuber1, Piotr Eder1, Krzysztof Linke1.   

Abstract

Secondary osteoporosis occurs as an isolated pathology or co-exists with types I and II osteoporosis. The gastroenterologist may come across osteoporosis or osteopenia in a patient with a gastrointestinal disease. This is often a young patient in whom investigations should be carried out and appropriate treatment initiated, aimed at preventing bone fractures and the formation of the best peak bone mass. Osteoporosis occurs in patients with the following conditions: Crohn's disease, ulcerative colitis, celiac disease, post gastrectomy patients, patients with short bowel syndrome, chronic hepatitis and cirrhosis, treated with steroids (steroid-induced osteoporosis) and patients using proton pump inhibitors chronically (state of achlorhydria). It is therefore necessary to approve a list of risk factors of secondary osteoporosis, the presence of which would be an indication for screening for osteoporosis, including a DXA study and the development of a separate algorithm for the therapeutic management of secondary osteoporosis accompanying gastrointestinal diseases, especially in premenopausal young women and young men, because there are currently no registered drugs with proven antifracture activity for this group of patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26935513     DOI: 10.17219/acem/33746

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  7 in total

1.  Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1 and IκB-NF-κB Pathways.

Authors:  Anna Li; Qian Cong; Xuechun Xia; Wai Fook Leong; James Yeh; Dengshun Miao; Yuji Mishina; Huijuan Liu; Baojie Li
Journal:  J Bone Miner Res       Date:  2017-05-09       Impact factor: 6.741

2.  Is there a relation between vitamin D, interleukin-17, and bone mineral density in patients with inflammatory bowel disease?

Authors:  Iwona Krela-Kazmierczak; Aleksandra Szymczak-Tomczak; Maciej Tomczak; Liliana Lykowska-Szuber; Piotr Eder; Marcin A Kucharski; Kamila Stawczyk-Eder; Katarzyna Waszak; Jacek Karczewski; Agnieszka Dobrowolska
Journal:  Arch Med Sci       Date:  2018-09-05       Impact factor: 3.318

3.  Nutritional Status and Bone Microarchitecture in a Cohort of Systemic Sclerosis Patients.

Authors:  Sabrina Paolino; Greta Pacini; Carlotta Schenone; Massimo Patanè; Alberto Sulli; Samir Giuseppe Sukkar; Adriano Lercara; Carmen Pizzorni; Emanuele Gotelli; Francesco Cattelan; Federica Goegan; Vanessa Smith; Maurizio Cutolo
Journal:  Nutrients       Date:  2020-06-01       Impact factor: 5.717

Review 4.  Biological Activities of Lactose-Based Prebiotics and Symbiosis with Probiotics on Controlling Osteoporosis, Blood-Lipid and Glucose Levels.

Authors:  Arijit Nath; Máté András Molnár; Attila Csighy; Kornélia Kőszegi; Ildikó Galambos; Klára Pásztorné Huszár; András Koris; Gyula Vatai
Journal:  Medicina (Kaunas)       Date:  2018-12-03       Impact factor: 2.430

5.  Diet and inflammatory bowel disease: The Asian Working Group guidelines.

Authors:  Ajit Sood; Vineet Ahuja; Saurabh Kedia; Vandana Midha; Ramit Mahajan; Varun Mehta; Ritu Sudhakar; Arshdeep Singh; Ajay Kumar; Amarender Singh Puri; Bailuru Vishwanath Tantry; Babu Ram Thapa; Bhabhadev Goswami; Banchha Nidhi Behera; Byong Duk Ye; Deepak Bansal; Devendra Desai; Ganesh Pai; Ghulam Nabi Yattoo; Govind Makharia; Hasitha Srimal Wijewantha; Jayanthi Venkataraman; K T Shenoy; Manisha Dwivedi; Manoj Kumar Sahu; Meenakshi Bajaj; Murdani Abdullah; Namrata Singh; Neelanjana Singh; Philip Abraham; Rajiv Khosla; Rakesh Tandon; S P Misra; Sandeep Nijhawan; Saroj Kant Sinha; Sawan Bopana; Sheela Krishnaswamy; Shilpa Joshi; Shivram Prasad Singh; Shobna Bhatia; Sudhir Gupta; Sumit Bhatia; Uday Chand Ghoshal
Journal:  Indian J Gastroenterol       Date:  2019-07-27

Review 6.  Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies.

Authors:  Maria Felicia Faienza; Annamaria Ventura; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2016-04-26       Impact factor: 5.555

7.  Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway.

Authors:  Rui-Xiong Huang; Jun Tao
Journal:  Mol Med Rep       Date:  2020-05-04       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.